ESMO - Eur. Oncology· @myESMO · X·· 5 hours agoScore45
Body
#ESMO26: In phase III trials, izalontamab brengitecan (#BispecificADC targeting EGFR and #HER3) and ruzaltatug rezetecan (#ADC targeting HER3) showed significant efficacy in patients with locally advanced or #metastatic #EGFRmutant #NSCLC
🔗 https://ow.ly/qpgc5100JU5
#InsightsbyESMO
75 views · 1 like · 1 repost · 0 replies
Conference abstracts
Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)
https://esmocongress.esmo.orgLBA50matched by Proffered paper 1: Breast cancer, early and advanced stage
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.orgSource: ESMO - Eur. Oncology · x.com